Cover Image
市場調查報告書

NPS Pharmaceuticals, Inc.的產品平台分析

NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 240934
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
NPS Pharmaceuticals, Inc.的產品平台分析 NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 42 Pages
簡介

本報告提供NPS Pharmaceuticals, Inc.上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

NPS Pharmaceuticals, Inc.的基本資料

NPS Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

NPS Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

NPS Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

NPS Pharmaceuticals, Inc.:開發中產品概況

  • 位於最終階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 位於第三階段的產品/聯合治療模式
  • 位於臨床實驗階段的開發中產品
    • 位於第二階段的產品/聯合治療模式
    • 位於第一階段的產品/聯合治療模式
  • 位於初期階段的開發中產品
    • 位於前臨床階段的產品/聯合治療模式

NPS Pharmaceuticals, Inc.:藥物簡介

  • shinakaruseto鹽酸鹽
  • 組換人類副甲狀腺素
  • teduglutide
  • NPSP-790
  • NPSP-795

NPS Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各類型分子
  • 各作用機制

NPS Pharmaceuticals, Inc.:最近的開發平台趨勢

NPS Pharmaceuticals, Inc.:暫停中的計劃

NPS Pharmaceuticals, Inc.:中止開發的開發中產品

  • 中止開發的開發中產品簡介
  • ALX-0646
  • isovaleramide

NPS Pharmaceuticals, Inc.:企業發表

NPS Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04885CDB

Global Markets Direct's, 'NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the NPS Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NPS Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of NPS Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of NPS Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the NPS Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate NPS Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of NPS Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the NPS Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of NPS Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of NPS Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of NPS Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • NPS Pharmaceuticals, Inc. Snapshot
    • NPS Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • NPS Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • NPS Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • NPS Pharmaceuticals, Inc. - Pipeline Products Glance
    • NPS Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • NPS Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • NPS Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • NPS Pharmaceuticals, Inc. - Drug Profiles
    • cinacalcet hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human recombinant parathyroid hormone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teduglutide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPSP-790
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPSP-795
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • NPS Pharmaceuticals, Inc. - Pipeline Analysis
    • NPS Pharmaceuticals, Inc. - Pipeline Products by Target
    • NPS Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • NPS Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • NPS Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • NPS Pharmaceuticals, Inc. - Recent Pipeline Updates
  • NPS Pharmaceuticals, Inc. - Dormant Projects
  • NPS Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ALX-0646
      • isovaleramide
  • NPS Pharmaceuticals, Inc. - Company Statement
  • NPS Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • NPS Pharmaceuticals, Inc., Key Information
  • NPS Pharmaceuticals, Inc., Key Facts
  • NPS Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • NPS Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • NPS Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014
  • NPS Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • NPS Pharmaceuticals, Inc. - Pre-Registration, 2014
  • NPS Pharmaceuticals, Inc. - Phase III, 2014
  • NPS Pharmaceuticals, Inc. - Phase II, 2014
  • NPS Pharmaceuticals, Inc. - Phase I, 2014
  • NPS Pharmaceuticals, Inc. - Preclinical, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • NPS Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • NPS Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • NPS Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014
  • NPS Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • NPS Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • NPS Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top